Evaluation of limited sampling strategies for tacrolimus

European Journal of Clinical Pharmacology

Volumn 63, Issue 11, 2007, Pages 1039-1044

  Op Den Buijsch, Robert A M ^a   Van De Plas, Afke ^a   Stolk, Leo M L ^a   Christiaans, Maarten H L ^a   Van Hooff, Johannes P ^a   Undre, Nas A ^b   Van Dieijen Visser, Marja P ^a   Bekers, Otto ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Astellas Pharma GmbH   (Germany)

Author keywords

AUC0 12; Limited sampling strategy; Tacrolimus; Trough level

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADULT; AREA UNDER CURVE; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; FEMALE; FORECASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TACROLIMUS; TIME FACTORS;

EID: 35248868319     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0354-9     Document Type: Article

References (26)

1. Mahalati K, Kahan BD (2000) Pharmacological surrogates of allograft outcome. Ann Transplant 5(2):14-23
2. Winkler M, Christians U (1995) A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 12(5):348-357
3. McMaster P, Mirza DF, Ismail T, Vennarecci G, Patapis P, Mayer AD (1995) Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 17(6):602-605
4. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43(10):623-653
5. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ (1996) An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 62(7):900-905
6. Kershner RP, Fitzsimmons WE (1996) Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62(7):920-926
7. Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U et al (1999) Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 31(1-2):296-298
8. Braun F, Schutz E, Peters B, Talaulicar R, Grupp C, Undre N et al (2001) Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc 33(3):2127-2128
9. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T et al (1994) Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. Transplant Proc 26(3):1804
10. Takahara S, Kokado Y, Kameoka H, Takano Y, Jiang H, Moutabarrik A et al (1994) Monitoring of FK 506 blood levels in kidney transplant recipients. Transplant Proc 26(4):2106-2108
11. Winkler M, Ringe B, Rodeck B, Melter M, Stoll K, Baumann J et al (1994) The use of plasma levels for FK 506 dosing in liver-grafted patients. Transpl Int 7(5):329-333
12. Armendariz Y, Pou L, Cantarell C, Lopez R, Perello M, Capdevila L (2005) Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 27(4):431-434
13. Balbontin FG, Kiberd B, Squires J, Singh D, Fraser A, Belitsky P et al (2003) Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc 35(7):2445-2448
14. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J et al (2004) Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43(11):741-762
15. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J et al (2005) AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67(6):2440-2447
16. Wong KM, Shek CC, Chau KF, Li CS (2000) Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 35(4):660-666
17. Stolk LM, Van Duijnhoven EM, Christiaans MH, van Hooff JP (2002) Trough levels of tacrolimus. Ther Drug Monit 24(4):573; author reply, 4
18. Pisitkun T, Eiam-Ong S, Chusil S, Praditpornsilpa K, Pansin P, Tungsanga K (2002) The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 34(8):3173-3175
19. Ku YM, Min DI (1998) An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit 20(2):219-223
20. Aumente Rubio MD, Arizon del Prado JM, Lopez Malo de Molina MD, Cardenas Aranzana M, Segura Saint-Gerons J, Lopez Granados A et al (2003) Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. Transplant Proc 35(5):1988-1991
21. Sgrosso JL, Araujo GL, Vazquez MC (2002) Tacrolimus pharmacokinetics in heart transplant. Transplant Proc 34(1):142-143
22. Ragette R, Kamler M, Weinreich G, Teschler H, Jakob H (2005) Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transplant 24(9):1315-1319
23. Ting LS, Villeneuve E, Ensom MH (2006) Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 28(3):419-430
24. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503-512
25. Meier-Kriesche HU, Kaplan B, Brannan P, Kahan BD, Portman RJ (1998) A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. Ther Drug Monit 20(4):401-407
26. David OJ, Johnston A (2001) Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 23(2):100-114